The Asthma Control Questionnaire (ACQ)1 was developed and validated to measure the primary clinical goal of asthma management as identified by international guidelines. They indicate that to achieve good control, treatment should minimise day and night time symptoms, activity limitation, airway narr...owing and rescue bronchodilator use and thus reduce the risk of life-threatening exacerbations and long-term morbidity. The importance of including all aspects of control in the assessment of individual patients was emphasised by a recent factor analysis which showed that clinical asthma is composed of distinct components which are not closely correlated with each other.6 However, in some studies it may not be possible to collect airway calibre or short-acting β2-agonists data. Previous analysis of non-clinical trial data suggested that when ACQ scores are analysed as group data, the heterogeneity of the way in which individual patients present with inadequate control is lost in the estimation of the mean and the need to measure each individual component of asthma control may become unnecessary. In this analysis, ACQ data from a clinical trial was used to evaluate the measurement properties (reliability, responsiveness, validity and interpretability), of three shortened versions of the ACQ. In addition, we have examined whether the precision and accuracy of estimating the effect of the intervention on asthma control was maintained when the two questions concerning airway calibre and short-acting β2-agonists use were omitted from the trial analysis.
more
Trastornos externalizantes
Capítulo D.1.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Carlos Gómez
Pediatría
Capítulo I.2
Editores: Laura Borredá Belda, Matías Irarrázaval & Andres Martin
Traducción: Alfonso Pastor Romero, Silvia Rodriguez Portillo, Carla Andreia Carvalho Gómez, María Tatiana Stefan & Paula Cox
Misceláneo
Capítulo J.10
Edición: Matías Irarrázaval & Andres Martin
Traducción: Fernanda Prieto-Tagle
Otros Trastornos
Capítulo H.1
Edición 2016
Edición: Matías Irarrázaval & Andres Martin
Revisión: Fernanda Prieto-Tagle & Jasna Raventós
Introducción
Capítulo A.13
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Julia Portillo
Trastornos del ánimo
Capítulo E.2
Editores: Matías Irarrázaval & Andres Martin Traductores:
Traducción: Fernanda Prieto-Tagle & Ester Mora
Otros trastornos
Capítulo H.5.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Iván Olle Llopis
Trastornos externalizantes
Capítulo D.1
Edición: Matías Irarrázaval & Andrés Martín
Traducción: Fernanda Prieto Tagle, Marta García Acuña
Misceláneo
Capítulo J.8
Edición: Matías Irarrázaval & Andres Martin
Traducción: Fernanda Prieto-Tagle & Gonzalo Ros
Psiquiatría y pediatría
Capítulo I.4
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Juan Jairo Ortiz Guerra
Introductión
Capítulo A.9
Edición: Matías Irarrázaval & Andres Martin
Traducción: Fernanda Prieto-Tagle & José Montejo
Otros trastornos
Capítulo H.5
Edición: Matías Irarrázaval & Andres Martin
Traducción: María Fernanda Prieto
Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment?
The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm...ents (e.g., interpersonal psychotherapy or cognitive behavioural therapy, including behavioural activation) or antidepressant medication (e.g., SSRIsi and tricyclic antidepressants) be considered in adults with moderate-severe depression. Health care workers need to know whether these treatments have different effects, including side-effects, in treating depressive disorder in the short and long term, in order to improve clinical decision-making.
more
Introducción
Capítulo A.6
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Jaume Morey
Introducción
Capítulo A.5
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Carlos Llanes
Introducción
Capítulo A.10
Editores: Juan José García-Orozco, Matías Irarrázaval & Andrés Martin
Traducción: Juan José García-Orozco, Paula Placencia Morán & Laura Revert
Otros trastornos
Capítulo H.4
Editores: Laura Borredá Belda, Matías Irarrázaval & Andres Martin
Traductores: Sara Diego Castaño, Laura Álvarez Bravos, Rebeca Santonja & Beatriz Ortega
Introducción
Capítulo A.3
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & María José Martínez
Trastornos externalizantes
Capítulo D.3
Edición: Matías Irarrázaval & Andres Martin
Traducción: Fernanda Prieto Tagle, Sofía Hacohen Domené